Generated by AI
IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases. IN8bio’s current pipeline centers on cell-based immunotherapies designed to target solid and hematologic tumors, with programs spanning allogeneic, autologous, iPSC-derived, and genetically modified approaches. Its lead and clinical programs include candidates being studied in glioblastoma and leukemia settings, reflecting the company’s emphasis on difficult-to-treat cancers and unmet medical needs. IN8bio also advances a T cell engager platform intended to broaden the reach of its immunotherapy portfolio across oncology and autoimmune indications. Based in New York, IN8bio plays a niche role in the biotechnology market as a developer of next-generation cellular medicines.
Website350 5th Avenue
New York, NY, 10118
United States
The latest articles about INAB.
Summary of Dec 22's posts. Generated by AI.
Summary of Dec 19's posts. Generated by AI.
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in the Sidoti Small-Cap Virtual Conference, held September 23-24, 2026. Mr. Ho will participate in one-on-one meetings with investors throughout the conference and deliver a company
Summary of Dec 19's posts. Generated by AI.
Investors talking about INAB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.